Efficacy and safety of neoadjuvant FLOT treatment for resectable gastric/gastroesophageal junction adenocarcinoma in Turkish and German patients; a real-world data.

ABSTRACT:

Background

Perioperative FLOT is the current standard of treatment in resectable gastric adenocarcinoma(GC) and adenocarcinoma of gastroesophageal junction(GEJC). However, many ethnicities remain underrepresented in clinical trials or are not differentiated in subgroup analyses, making it unclear whether outcomes, especially major pathological response (mPR), vary across different populations.

Methods

Turkish(Tp) and German(Gp) patients with resectable GC/GEJC who received perioperative FLOT were evaluated retrospectively. The primary endpoint was mPR which was defined as pathological complete response or near-complete response. The secondary endpoints were disease-free survival(DFS), overall survival(OS), and safety.

Results

Forty-seven Tp and 55 Gp were included. Wh

SUBMITTER: Eroglu I 

PROVIDER: S-EPMC12613602 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature